Calder Biosciences
NYC, US · 1 known investors
Calder Biosciences is a molecular engineering company developing novel vaccines against RSV, influenza, and other viral infections using platform technology for vaccine design and manufacturing.
Investors · 1
Non-dilutive funding · 4 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2020 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $299.7K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2018 | $2.9M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2018 | $599.7K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.